...
首页> 外文期刊>Neurobiology of learning and memory >Effects of cannabinoids infused into the dorsal hippocampus upon memory formation in 3-days apomorphine-treated rats.
【24h】

Effects of cannabinoids infused into the dorsal hippocampus upon memory formation in 3-days apomorphine-treated rats.

机译:阿扑吗啡治疗3天后海马中注入大麻素对记忆形成的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In the present study, the effects of intra-dorsal hippocampus (intra-CA1) injection of cannabinoid receptor agents on memory formation have been investigated in 3-days apomorphine-treated rats. Step-through inhibitory avoidance task of memory has been used to examine retrieval of memory formation, 24h after training. Apomorphine was injected subcutaneously (S.C.), once daily for 3-days followed by 5 days free of the apomorphine before training. Bilateral post-training intra-CA1 infusions of the non selective CB1-CB2 receptor agonist, WIN55,212-2 (0.1, 0.25 and 0.5 microg/rat), dose-dependently shortened the step-through latency, suggesting amnesia by the drug, whereas bilateral post-training intra-CA1 micro-injections of the selective CB1 receptor antagonist, AM251 (25, 50 and 100 ng/rat), did not affect memory formation. Intra-CA1 infusions of AM251 and WIN55,212-2, two min apart, modify the WIN55,212-2-induced reduction of step-through latency. Furthermore, the deleterious effect of WIN55,212-2 (0.25 microg/rat) was completely abolished in rats previously given apomorphine (0.5 and 1 mg/kg/day, S.C.) for 3 days. This prevention of WIN55,212-2-induced amnestic-like effect was counteracted by the dopamine D2 receptor antagonist, sulpiride (0.25, 0.5 and 1 mg/kg/day x 3-days, S.C.), administered 30 min before each injection of apomorphine (0.5 mg/kg/day x 3-days, S.C.). The D1 receptor antagonist, SCH 23390 (0.01, 0.02, 0.07 and 0.1 mg/kg/day x 3-days, S.C.), was ineffective in this respect. The results suggest that subchronic apomorphine treatment may induce dopamine D2 receptor sensitization, which in turn prevented amnesia induced by WIN55,212-2.
机译:在本研究中,已在3天的阿扑吗啡治疗大鼠中研究了背海马(CA1内)注射大麻素受体剂对记忆形成的影响。在训练后24小时,记忆的逐步抑制性避免任务已用于检查记忆形成的恢复。将阿扑吗啡皮下注射(S.C.),每天一次,持续3天,然后在训练前5天无阿扑吗啡。非选择性CB1-CB2受体激动剂WIN55,212-2(0.1、0.25和0.5微克/大鼠)的双训练后CA1输注剂量依赖性地缩短了逐步潜伏期,表明该药物引起了健忘症,而选择性CB1受体拮抗剂AM251(分别为25、50和100 ng /大鼠)的双边CA1内显微注射不会影响记忆形成。相隔两分钟的AM251和WIN55,212-2的CA1内输注可改善WIN55,212-2诱导的逐步延迟的减少。此外,在先前给予阿扑吗啡(0.5和1mg / kg /天,S.C。)3天的大鼠中,WIN55,212-2(0.25μg/大鼠)的有害作用被完全消除。多巴胺D2受体拮抗剂舒必利(0.25、0.5和1 mg / kg /天x 3天,SC)在每次注射前30分钟给药,抵消了WIN55,212-2-诱导的记忆删除样作用的预防。阿扑吗啡(0.5 mg / kg /天x 3天,SC)。在这方面,D1受体拮抗剂SCH 23390(0.01、0.02、0.07和0.1mg / kg /天×3天,S.C。)无效。结果表明,亚慢性阿扑吗啡治疗可能会引起多巴胺D2受体致敏,从而防止WIN55,212-2引起的健忘症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号